The American journal of psychiatry最新文献_第9页

Putting the Amygdala and Hippocampus in PTSD to Rest. 让PTSD患者的杏仁核和海马体休息。

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20260188

Paul Frewen, Andrew Nicholson

引用次数: 0

Correction to Zwicker et al. 对Zwicker等人的更正。

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20220476correction

引用次数: 0

Brain Imaging Research on Posttraumatic Stress Disorder: Using Big Data to Guide Clinical Applications. 创伤后应激障碍脑成像研究：利用大数据指导临床应用

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20260255

Daniel S Pine

引用次数: 0

Sex Differences in Psychiatric Comorbidity Among Adults With Substance Use Disorders. 成人物质使用障碍精神共病的性别差异。

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20260090

Mark Olfson

引用次数: 0

The Next DSM, PTSD, and Substance Use Disorders. 下一个DSM， PTSD和物质使用障碍。

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20260294

Ned H Kalin

引用次数: 0

Psychiatric Comorbidities in Substance Use Disorders: Sex-Based Differences in a National Real-World Clinical Sample. 物质使用障碍的精神共病：国家真实世界临床样本中基于性别的差异。

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 Epub Date: 2026-03-11 DOI: 10.1176/appi.ajp.20250828

Eduardo R Butelman, Yuefeng Huang, Rita Z Goldstein, Nelly Alia-Klein

{"title":"Psychiatric Comorbidities in Substance Use Disorders: Sex-Based Differences in a National Real-World Clinical Sample.","authors":"Eduardo R Butelman, Yuefeng Huang, Rita Z Goldstein, Nelly Alia-Klein","doi":"10.1176/appi.ajp.20250828","DOIUrl":"10.1176/appi.ajp.20250828","url":null,"abstract":"Objective: Substance use disorders (SUDs) are associated with risk of psychiatric comorbidities, with inconsistent sex differences across studies. The objective of this study was to determine odds of psychiatric comorbidities based on sex in persons with a primary diagnosis of opioid, alcohol, or cannabis dependence, using a national clinical dataset.Methods: This was a cross-sectional study of data from state-funded and state-run mental health programs in 2022 (Mental Health Client-Level Data, from the U.S. Substance Abuse and Mental Health Services Administration). Data were obtained from adults (age ≥18 years) with a primary diagnosis of either opioid (N=28,808), alcohol (N=23,281), or cannabis dependence (N=5,961). Data from individuals with each SUD were examined for psychiatric comorbidity outcomes, based on secondary diagnoses of an anxiety disorder, bipolar disorder, a depressive disorder, schizophrenia or other psychotic disorder, or a trauma- and stressor-related disorder versus no comorbidity. Data were analyzed with multinomial logistic regressions, examining sex, race, ethnicity, and age as predictors.Results: Males with a primary diagnosis of opioid, alcohol, or cannabis dependence had lower adjusted odds of anxiety, bipolar, depressive, and trauma- and stressor-related disorders compared to females. However, males with opioid or cannabis dependence had higher adjusted odds of schizophrenia or other psychotic disorders compared to females. Adjusted analyses also detected associations of race and ethnicity with specific comorbidities.Conclusions: In this recent national clinical dataset, sex-based differences were observed in specific psychiatric comorbidities for each of these three SUDs. Future studies should examine biopsychosocial mechanisms that underlie these differences, with the goal of improving personalized care.","PeriodicalId":520786,"journal":{"name":"The American journal of psychiatry","volume":" ","pages":"355-363"},"PeriodicalIF":14.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circuit-Targeted TMS for PTSD: Where, When, How, and for Whom? 电路定向经颅磁刺激治疗创伤后应激障碍：地点，时间，方式和对象？

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20260231

Ryan D Webler, Joshua C Brown, Shan H Siddiqi

引用次数: 0

National Census Data on Autism in Brazil: Historic Advances and Persistent Inequities. 巴西自闭症的全国人口普查数据：历史性的进步和持续的不平等。

IF 14.7

The American journal of psychiatry Pub Date : 2026-05-01 DOI: 10.1176/appi.ajp.20251204

João Ricardo Mendes de Oliveira, Lucas Rafael Ferreira Soares, Maria Helena Negreiros Sieber Padilla

引用次数: 0

Disclosure of Editors' Financial Relationships. 编辑财务关系的披露。

IF 14.7

The American journal of psychiatry Pub Date : 2026-04-01 DOI: 10.1176/appi.ajp.26183002

引用次数: 0

Approach Bias Modification as an Add-On to Smoking Cessation Treatment: A Randomized Controlled Trial. 方法偏倚修正作为戒烟治疗的附加：一项随机对照试验。

IF 14.7

The American journal of psychiatry Pub Date : 2026-04-01 Epub Date: 2026-02-04 DOI: 10.1176/appi.ajp.20250189

Charlotte E Wittekind, Keisuke Takano, Franziska Motka, Markus H Winkler, Gabriela G Werner, Thomas Ehring, Tobias Rüther

{"title":"Approach Bias Modification as an Add-On to Smoking Cessation Treatment: A Randomized Controlled Trial.","authors":"Charlotte E Wittekind, Keisuke Takano, Franziska Motka, Markus H Winkler, Gabriela G Werner, Thomas Ehring, Tobias Rüther","doi":"10.1176/appi.ajp.20250189","DOIUrl":"10.1176/appi.ajp.20250189","url":null,"abstract":"Objective: Smoking is associated with an approach bias toward smoking-related stimuli. Approach bias modification (ApBM), a computerized training specifically designed to modify this approach bias, has shown positive effects in patients with alcohol use disorder; however, its efficacy as an add-on in smoking cessation treatment is inconclusive. The aim of this clinical trial was to investigate whether ApBM as an add-on to smoking cessation treatment results in higher 6-month prolonged abstinence rates compared to two control conditions.Methods: In this randomized, controlled, double-blind, single-center superiority trial, 351 participants received a 1-day cognitive-behavioral smoking cessation treatment (treatment as usual [TAU]) and were subsequently randomized to either TAU+ApBM (N=119), TAU+sham training (N=115), or TAU only (N=117). Training sessions were conducted over 7 days. The primary outcome was prolonged abstinence at 6-month follow-up. Participants were classified as either nonsmoking (continuous abstinence for 6 months, ≤5 cigarettes since quit attempt, and breath CO level ≤9 ppm) or relapsed (no objective verification of smoking status, breath CO level ≥10 ppm, >5 cigarettes since quit attempt).Results: In the intention-to-treat analyses, abstinence rates at 6 months were 19.3% (95% CI=12.13, 26.53) for TAU+ApBM, 17.4% (95% CI=10.36, 24.42) for TAU+sham training, and 16.2% (95% CI=9.46, 23.02) for TAU only, with no significant differences between groups.Conclusions: This large-scale clinical trial demonstrates that TAU+ApBM is not significantly superior to TAU+sham training or TAU only. ApBM has been included in Australian and German alcohol use disorder treatment guidelines, but this randomized controlled trial shows that positive effects do not apply to tobacco use disorder.","PeriodicalId":520786,"journal":{"name":"The American journal of psychiatry","volume":" ","pages":"240-250"},"PeriodicalIF":14.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146115429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0